Merck & Co., Inc. Announces Robust Integrated Pipeline With More Than 20 Medicines and Vaccines in Late-Stage Development

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck & Co., Inc. (NYSE: MRK) today announced its updated, newly integrated, late-stage pipeline following its recent merger with Schering-Plough. The new pipeline features a broad and diversified portfolio of investigational medicines and vaccines, including more than 20 candidates in Phase III or under regulatory review, and more than 20 candidates in Phase II of development.